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ABSTRACT: 
 Background: Recombinant human erythropoietin (rHuEPO) is frequently abused by 
athletes as a performance-enhancing drug, despite being prohibited by the World Anti-
Doping Agency. Although the methods to detect blood doping, including rHuEPO injections, 
have improved in recent years, they remain imperfect.  
Methods: In a proof-of-principle study, we identified, replicated and validated the 
whole-blood transcriptional signature of rHuEPO in endurance-trained Caucasian males at 
sea-level (n = 18) and Kenyan endurance runners at moderate altitude (n = 20), all of whom 
received rHuEPO injections for four weeks. 
Results: Transcriptional profiling shows that hundreds of transcripts were altered by 
rHuEPO in both cohorts. The main regulated expression pattern, observed in all participants, 
was characterised by a “rebound” effect with a profound up-regulation during rHuEPO and a 
subsequent down-regulation up to four weeks post administration. The functions of the 
identified genes were mainly related to the functional and structural properties of the red 
blood cell. Of the genes identified to be differentially expressed during and post rHuEPO, we 
further confirmed a whole blood 34-transcript signature that can distinguish between samples 
collected pre, during and post rHuEPO administration. 
Conclusion: By providing biomarkers that can reveal rHuEPO use, our findings 
represent an advance in the development of new methods for the detection of blood doping.  
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INTRODUCTION 
Erythropoietin is a hormone that regulates the production of new red blood cells 
(erythropoiesis) (18). Administration of recombinant human erythropoietin (rHuEPO) 
improves sporting performance (10) and hence is frequently subject to abuse by athletes, 
despite being prohibited by the World Anti-Doping Agency (WADA). The direct detection of 
rHuEPO doping is challenging because rHuEPO is structurally very similar to endogenous 
erythropoietin and rapidly disappears from the circulation. The Athlete Biological Passport 
(ABP) was introduced as a new tool to provide indirect evidence for the use of 
erythropoiesis-stimulating agents such as rHuEPO by identifying abnormal intra-individual 
variability in selected blood parameters over time (34). While approaches to detect blood 
doping, including rHuEPO injections, are improving, the declarations of confessed dopers 
emphasize the need for further refinement of current detection methods. 
The typical goal of ‘omics’-based research is the identification of new and specific 
molecular biomarkers for the diagnosis, monitoring and prognosis of diseases. The same 
approach can be used for monitoring the efficacy of drug therapy (22). Here, we applied an 
‘omics’-based approach in human volunteers to generate a transcriptional signature of 
rHuEPO for anti-doping purposes. We first describe the specific alterations of the blood 
transcriptional profiles induced by rHuEPO administration in two distinct and independent 
groups. We then validate a whole blood 34-transcript signature using another quantitative 
gene technology and performed in a subset of fifty selected genes. Finally, we demonstrate 
the implications of our findings for anti-doping strategies. The identification of the blood 
transcriptional signature of rHuEPO provides the basis for the development of new and 
improved models to detect blood doping. Our study also provides a broad range of 
transcriptional biomarkers relevant for understanding the variability in responsiveness to 
rHuEPO therapy. 
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METHODS 
Experimental design 
Eighteen endurance-trained Caucasian males at sea-level (SCO; 26.0 ± 4.5 years, 74.8 
± 7.9 kg, 179.8 ± 5.4 cm) (10) and twenty east African endurance runners from the Kalenjin 
tribe in Kenya (KEN; 26.4 ± 4.1 years, 56.6 ± 4.7 kg, 171.8 ± 6.4) at moderate altitude 
(~2150 m) participated in the study. All subjects underwent a medical assessment and 
provided written informed consent to participate. Subjects were requested to maintain their 
normal training but abstain from official sporting competition for the duration of the research 
study (16). This study was approved by the Ethics Committees of the University of Glasgow 
(Scotland, UK) and Moi University (Kenya) and conformed to the Declaration of Helsinki. 
The subjects subcutaneously self-injected 50 IU·kg-1 body mass of rHuEPO (NeoRecormon, 
Roche) every second day for four weeks (Figure 1A). Daily oral iron supplementation (~ 100 
mg of elemental iron, Ferrous Sulphate Tablets, Almus) was given during the four weeks of 
rHuEPO administration. 
 
Blood sampling and RNA extraction 
After ten minutes of rest in the supine position, 3 mL of whole blood was collected 
into Tempus Blood RNA tubes (Life Technologies) from an antecubital vein in triplicate at 
baseline, during rHuEPO administration and for four weeks after rHuEPO administration. 
The Tempus tubes were vigorously mixed immediately after collection, incubated at room 
temperature for three hours and stored between -20˚C and -80˚C before RNA extraction. 
Eight time points per subjects were selected for gene expression analysis (Figure 1A-B). 
RNA was extracted using the MagMAX for stabilized blood tubes RNA isolation kit (Life 
Technologies) or the Tempus Spin RNA isolation kit (Life Technologies). RNA yield was 
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determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific) and the RNA 
integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent technologies) showing a 
quality of RNA integrity number of 8.5 ± 0.9 (95% confidence intervals (CI) 8.4 to 8.6 and 
ranging from 5.0 to 9.8). RNA was stored at -80°C until further analysis. 
 
Microarray experiment and data analysis 
Eighteen subjects in each cohort were selected for the microarray experiment. 
Extracted RNA was prepared using the Illumina TotalPrep RNA Amplification Kit (Life 
Technologies). The RNA amplification consists of synthesizing cRNA by in vitro 
transcription from the cDNA produced by reverse transcription from 500 ng of RNA. 750 ng 
of the purified labeled cRNA samples were then randomly hybridized to the Illumina 
HumanHT-12 v4.0 Expression BeadChip arrays, which contain more than 47,000 probes, 
following the manufacturers’ recommended procedures (Illumina). The Bead arrays were 
scanned on the Illumina BeadArray Reader and raw intensity values were saved in Illumina 
GenomeStudio software. Following the manufacturer's instructions Illumina GenomeStudio 
quality control metrics were used to assess the quality of the samples; all samples passed 
these assessments. 
For normalisation, Illumina GenomeStudio software was used to subtract background 
and to perform quantile normalisation. Using R software environment (http://www.r-
project.org/), normalised probe level intensities were then log2 transformed after adding a 
small constant to avoid negative values as well as to reduce the influence of probes with low 
signal intensities close to the background noise. The constant’s value was chosen after 
inspection of scatter plots of the two baseline samples from each individual. To remove the 
array effect a linear model was fitted to the each gene’s data using array as the predictor, and 
the coefficients for each array were removed from each value. These normalised data were 
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used for all downstream analyses. Rank Products analysis (4) with a 5% false discovery rate 
(3) was used to identify the differentially expressed transcripts during and post rHuEPO 
administration compared to baseline values. An additional 1.5 fold-change threshold was 
applied for a more stringent analysis. The differences in genes expression between the two 
cohorts by time-interaction were analysed using R-package Limma (linear models for 
microarray) (33) with a 5% false discovery rate (3). Functional analysis of differentially 
expressed genes was performed using Ingenuity Pathway Analysis (Ingenuity Systems) with 
Fisher’s exact test to calculate a P value determining the probability that each biological 
function and/or network assigned to the identified genes was due to chance alone, with a 
Benjamini-Hochberg correction for multiple testing applied. All microarray data are available 
in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-
MTAB-2874. 
 
QuantiGene Plex experiment and data analysis 
QuantiGene Plex assay (Affymetrix) was used for further confirmation of the 
microarray results. The QuantiGene Plex assay combines branched DNA (bDNA) signal 
amplification and xMAP profiling magnetic beads technologies (Luminex). The bDNA 
enables target RNA quantification by amplifying the reporter signal rather than target 
sequences and the xMAP fluorescent microspheres or “beads” are used as a support to 
capture specific RNA molecules (12). The MicroArray Quality Control (MAQC) project has 
demonstrated the good precision and accuracy of the QuantiGene Plex assay (5). 
A subset of fifty identified genes was selected for confirmation using QuantiGene 
Plex. The selection of these fifty genes was based on the following criteria: magnitude of the 
changes in expression; relative expression above background level; low inter-individual 
responses in gene expression pattern; consistency between the Illumina probes targeting 
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different transcripts for the same gene; biological relevance. Eighteen and twenty subjects in 
the SCO and KEN cohorts were selected for the QuantiGene Plex experiment, respectively. 
Two different RNA inputs of 100 and 200 ng for each sample were hybridized and amplified 
using the QuantiGene Plex assay and following the manufacturers’ recommended procedures 
(Affymetrix). The fluorescence signal was read on the MAGPIX (Luminex) and median 
fluorescence intensity (MFI) values were saved using xPonent software. Data were exported 
to R software environment where background subtraction, log2 transformation and 
normalisation to four housekeeping genes (ACTB, ACTR10, MRFAP1 and RAB11A) were 
performed. These normalised data were used for all downstream analyses. R-package Limma 
(33) with a 5% false discovery rate (3) was used to confirm expression profiles. 
 
Blood parameters analysis 
Haematology analysis including reticulocyte percentage and haematocrit was 
performed from homogenized whole blood collected in EDTA tubes using fluorescence flow 
cytometry and hydrodynamic focusing (Sysmex XT-2000i, Sysmex). Reticulocyte percent 
data were exported to R software environment where log ratio compared to baseline values 
was calculated. The reticulocyte effect was controlled by regression modelling in the R-
package Limma (33) using the regression coefficient as a scaling factor. The curve of the 
relationship between reticulocyte and genes which remained significantly differentially 
expressed after controlling for the effect of reticulocyte was fitted using polynomial local 
regression (loess). 
 
Prediction using k-nearest neighbour 
 For class prediction and estimation of the discriminatory performance, we used the k-
nearest neighbours method from the R-package “class”, with six neighbours. The 34 genes 
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validated by QuantiGene Plex were used for prediction of samples collected pre, during and 
post rHuEPO administration as well as for prediction of samples collected at 2 days after the 
first rHuEPO injection. The prediction model was trained using five-fold cross-validation on 
thirty randomly selected subjects (training set: SCO; n = 14 and KEN; n = 16). This model 
was then used to predict the classification of the samples in the remaining eight subjects (test 
set: SCO; n = 4 and KEN; n = 4) and to determine sensitivity, specificity and 95% CI. 
 
RESULTS: 
rHuEPO administration profoundly alters blood transcriptional profiles 
To identify changes in the blood transcriptome after rHuEPO administration, we first 
generated genome-wide whole-blood transcriptional profiles from the SCO cohort. The 
previously published phenotypic results confirmed that rHuEPO administration increased red 
blood cell mass and improved exercise performance (10). Transcriptional profiling shows that 
hundreds of transcripts were altered by rHuEPO administration (Figure 1C). Using a 
combination of changes in expression-level and robust statistical criteria, we identified a 41-
transcript signature, distinct from baseline values, at two days after the first injection that 
remained altered throughout rHuEPO administration (Figure 1B-C and supplementary file 
Data Set S1). At the same time, a distinct 10-transcript signature was defined by differential 
expression after rHuEPO administration that remained differentially expressed up to four 
weeks post administration (Figure 1B-C and supplementary file Data Set S2). 
 
Similar changes in blood transcriptional profiles were observed in all individuals  
In order to replicate our findings, we then applied a similar genome-wide 
transcriptional approach to the independent KEN cohort who underwent a similar rHuEPO 
administration regimen. The initial findings were replicated and only minimal significant 
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differences were found between the two groups. More precisely, only three transcripts 
(DARC, JAK3 and CCDC71) were found to be differentially regulated between SCO and 
KEN. 
Of the genes already differentially expressed two days after the first injection 
compared to baseline in the SCO and KEN cohorts, 32 transcripts were commonly regulated, 
while 5 transcripts were commonly regulated post administration in the two groups (Table 1, 
Figure 1C and supplementary files Data Sets S1-S4). The main regulated expression pattern 
of the identified signature was characterised by a “rebound” effect with a profound up-
regulation during rHuEPO and a subsequent down-regulation up to four weeks post 
administration. The same transcriptional signature pattern was observed in all participants. 
CA1 gene was selected to exemplify the signature pattern observed in all 32 transcripts 
(Figure 1D and supplementary files Data Sets S1-S4). 
 
Whole-blood transcriptional signature of rHuEPO reflects distinct changes in gene 
expression and production of new red blood cells 
The genes profoundly up-regulated during rHuEPO and subsequently down-regulated 
post administration were mainly related to haematological, haematopoietic and 
cardiovascular system development and function (Figure 2A), such as the differentiation of 
the red blood cells (Figure 2B) and in agreement with the observed changes in blood 
parameters (Figure 2C). Validation, using another quantitative gene technology and 
performed in a subset of fifty selected genes, confirmed the whole blood 34-transcript 
signature (Figure 3 and Table 2). 
Although reticulocytes have shed their nucleus, they retain quantities of residual 
nucleic acid material (11). As such, we tested the hypothesis that the identified whole blood 
34-transcript signature may reflect the relative proportion of immature red blood cells 
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(reticulocytes) compared to white blood cells. The rHuEPO-induced changes in expression 
observed in the identified genes were correlated with the changes in reticulocyte percentage 
(Table 2). Nevertheless, even after controlling for the effect of reticulocyte, changes in gene 
expression compared to baseline values still reached significance levels in several genes 
(Figure 4 and Table 2). In particular, four genes (EPB42, SELENBP1, SLC4A1, and PITHD1) 
showed that the blood transcriptional signature can be more sensitive than reticulocyte 
percentage in detecting changes in blood profiles induced by only one rHuEPO injection 
(Figure 4 and Table 2). 
 
Discriminatory performance and anti-doping implications 
The k-nearest neighbour prediction model was able to distinguish between samples 
collected pre, during and post rHuEPO administration with overall sensitivity and specificity 
of 79.4% (95% CI 74.8 to 83.9%) and 94.7% (95% CI 92.2 to 97.3%), respectively (Table 3). 
Finally, and most importantly for current anti-doping challenges, the k-nearest neighbour 
prediction gave a sensitivity of 58.6% (95% CI 42.7 to 74.4%) and a specificity of 97.4% 
(95% CI 93.8 to 100%) for specifically distinguishing samples collected at baseline and at 
two days after only one rHuEPO injection, which would typically remain undetectable by the 
current tests using standard blood parameters (1). 
 
DISCUSSION AND CONCLUSIONS: 
 rHuEPO is frequently abused by athletes as a performance-enhancing drug, despite 
being prohibited by WADA. Using transcriptional profiling from whole-blood, we provide 
proof-of-principle for a new transcriptionally-enhanced model for the detection of rHuEPO 
doping. In this study, we first identified the changes in blood transcriptional profiles in 
perturbed erythropoiesis via rHuEPO administration in endurance-trained individuals in 
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Scotland. The results were then replicated in KEN and only minimal significant differences 
were found with SCO. Some of the only few differences observed between the two groups, 
such as in DARC and JAK3, may be explained by gene polymorphisms. For instance, 
polymorphisms in DARC are the basis of the Duffy blood group system which is associated 
with resistance to Plasmodium vivax malaria (44). Using another quantitative gene 
technology and performed in a subset of fifty selected genes, we then validated the whole 
blood 34-transcript signature. Finally, we tested the discriminatory performance of this blood 
transcriptional signature. We anticipate our results to be the starting point for a new 
transcriptionally-enhanced model for the detection of blood doping. 
 
Biological functions of the identified signature 
The whole-blood transcriptional signature of rHuEPO administration showed 
biologically coherent changes in gene expression. In particular, the functional and structural 
components of the red blood cells were dominant in the 34-transcript signature; for example, 
the haem synthesis (ALAS2, FECH and SNCA) (28, 30), the transport of oxygen and carbon 
dioxide (HBD, BPGM, CA1 and SLC4A1) (13, 14, 24), the organisation and connectivity of 
the red blood cell membrane (EPB42, TMOD1, GYPE and RBM38) (15, 17, 29, 36), the 
control of reactive oxygen species which can potentially induce cell apoptosis (BCL2L1 and 
SELENBP1) (26, 32), the regulation of the cell cycle and the differentiation of blood cells 
during erythropoiesis (FBXO7) (7), the purine metabolism (GMPR and GUK1), as well as 
genes of unknown function in the red blood cell but which were previously reported to be 
relevant to the red blood cell biology (TRIM58, CSDA, DCAF12, FAM46C, STRADB, 
ADIPOR1, PITHD1 and UBXN6) (6, 37, 40, 43). These findings support the view that the 
gene set identified here is enriched for genes involved in the biological processes related to 
the red blood cell, particularly during late-stage erythropoiesis. 
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From a clinical perspective, rHuEPO and other erythropoiesis stimulating agents are 
widely used in the treatment of anaemia. The introduction of rHuEPO was a paradigm-shift 
in the treatment of patients with anaemia due to, for example, chronic kidney disease as it 
dramatically reduced the use of blood transfusions and their associated morbidity (20). 
However, there is a need to better understand the variability as well as to predict and improve 
responsiveness to rHuEPO therapy (20). As such, our data provides a series of candidate 
biomarkers relevant to investigating the variability in response to rHuEPO treatment. 
 
Detection of early changes in erythropoiesis 
In the bone marrow, erythropoietin binds to the erythropoietin receptor and activates 
the Jak2-STAT5 signalling cascade which then stimulates the survival, proliferation and 
differentiation of red blood cell progenitors (18) without affecting the white blood cells 
production (19). Following the initial development and maturation in the bone marrow, the 
reticulocytes are then released in the blood stream before developing into mature red blood 
cells. Because reticulocytes still retain quantities of residual nucleic acid material (11), the 
identified whole blood 34-transcript signature may reflect the relative proportion of immature 
red blood cells (reticulocytes) compared to white blood cells. The correlation between the 
rHuEPO-induced changes in gene expression with the changes in reticulocyte percentage is in 
agreement with previously reported correlation between red cell distribution width, which 
often reflects a higher percentage of reticulocytes, and a cluster of 57 genes that include 
several genes also identified in the present study, such as EPB42, SLC4A1, ALAS2, TMOD, 
CSDA, GMPR and BPGM (41). Nonetheless, changes in gene expression still reached 
significance levels in several genes even after controlling for the effect of reticulocyte. 
The observation that the blood transcriptional signature, in particular four genes 
(EPB42, SELENBP1, SLC4A1, and PITHD1), can be more sensitive than reticulocyte 
DURUSSEL et al  TRANSCRIPTIONAL SIGNATURE OF rHuEPO 
13 | 
percentage in detecting early changes in erythropoiesis in whole blood is particularly relevant 
for the challenge that faces current anti-doping methods to detect small doses of rHuEPO. 
Indeed, in order to minimise the risk of being caught via the ABP, it is well recognised that 
athletes are now using so-called “microdoses” of rHuEPO which allegedly range from 10 to a 
maximum of 40 IU·kg-1 body mass. These small or “microdoses” of rHuEPO aim to increase 
red blood cell mass while avoiding large fluctuation in the ABP blood markers and/or 
“normalising” these markers after blood manipulations such as autologous blood transfusion, 
as well as minimising the detection window for conventional direct methods (23). However, 
the ABP did not detect a single case of rHuEPO when a microdosing strategy was adopted 
(1). The k-nearest neighbour prediction results for specifically distinguishing samples 
collected at baseline and at two days after only one rHuEPO injection are promising results in 
order to detect a small dose of rHuEPO. The k-nearest neighbour classifier is a robust method 
that has been shown to be very effective in gene expression classification (9). However, it is 
essentially a naïve machine learning algorithm that does not take into account when the 
sample was taken, for example. There thus remains scope for the discriminatory performance 
to be even further improved by using more sophisticated methods, such as the ABP adaptive 
Bayesian model (35), once normal physiological molecular reference profiles are generated. 
 
Study limitations 
The fact that the present study was not blinded and did not include a control group 
may limit the interpretations of the direct applications of the findings. However, participants 
were able to act as their own controls to an extent and any placebo effects are unlikely to 
have yielded the extent of differential expression and the characteristic profiles observed in 
differentially regulated genes. In addition, based on the recent admissions by confessed 
dopers, the rHuEPO dose regimen used in this study (i.e. 50 IU·kg-1 body mass every two 
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days for four weeks) does not closely reproduce the strategy of “microdoses” rHuEPO doping 
typically currently used by athletes (23). However, this study was not designed to exactly 
mimic drug taking behaviour but rather it was designed as a proof-of-principle of the 
transcriptomic approach to detection of rHuEPO. Further, as a consequence of the promising 
results discussed here, we have already designed a randomised, double-blind, placebo-
controlled cross-over study involving microdosing (25). 
 
Implications for anti-doping strategies and conclusions 
Earlier studies, limited by small number of subjects or animals and using the serial 
analysis of gene expression (SAGE) method, already reported some modifications of blood 
gene expression after rHuEPO administration (2, 38, 39). Here we provide the first complete 
description of the human blood transcriptional signature of altered erythropoiesis in response 
to rHuEPO administration. The k-nearest neighbour approach can distinguish between 
samples collected pre, during and post rHuEPO administration. Moreover, a transcriptionally-
enhanced model can potentially reduce the logistical challenges and cost incurred in sample 
collection and analysis. Current anti-doping blood samples have important logistic and cost 
implications since blood samples must be shipped refrigerated (4ºC) and analysed within 48 h 
of collection (42), whereas the blood samples, RNA stabilised in Tempus tubes (Life 
Technologies) of a transcriptionally-enhanced model are easy to handle and stable for 5-7 
days at room temperature and for years when kept frozen prior to analysis (8, 21, 27, 31). 
However, further validations using rHuEPO doping regimen more similar to what is currently 
thought to be used, with smaller doses and more sophisticated ABP-like modelling methods 
as well as the generation of normal physiological reference ranges, are required before the 
blood transcriptional signature-based approach delivers on its promise to add a new 
dimension to the current detection methods used by WADA.  These promising results might 
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also mean that other banned substances could be detectable with transcriptomic approaches. 
However, their effectiveness may vary according to the substance considered and the tissue 
type available. 
In summary, our results provide evidence to support a transcriptionally enhanced 
approach for the detection of blood doping. Our study also provides new insights into a broad 
range of transcriptional biomarkers relevant for understanding the biological mechanisms 
involved in erythropoiesis.	
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Figure Captions: 
 
Figure 1. Identification of a distinct whole-blood transcriptional signature of rHuEPO. 
(A) Experimental design and time points selected for transcriptomic analysis. (B) Time 
points, comparisons and colour codes. Labels for comparisons: A=EPO3 (2 days into EPO 
dosing) vs. Base1 (first baseline measurement), B=EPO4 (2 weeks into EPO) vs. Base1, 
C=EPO5 (4 weeks into EPO) vs. Base1, D=Post6 (1 week post EPO) vs. Base1, E=Post7 (2 
weeks post EPO) vs. Base1, F=Post8 (4 weeks post EPO) vs. Base1. (C) Venn diagrams of 
transcripts up- (↑) and down-regulated (↓) during (top panels) and after (bottom panels) 
rHuEPO administration compared to baseline in SCO (n = 18; left panels) and KEN (n = 18; 
right panels). See supplementary files Data Sets S1-S4 for the lists of transcripts. (D) 
Individual changes in CA1 gene, selected as a typical example. Changes are reported as log 
ratios compared to the average baseline values. 
 
Figure 2. Haematological related functions are dominant in the rHuEPO transcriptional 
signature. (A) Top three regulated Physiological System Development identified by 
Ingenuity Pathway Analysis of the transcripts altered by rHuEPO across the time points. 
Labels for comparisons: A=EPO3 (2 days into EPO dosing) vs. Base1 (first baseline 
measurement), B=EPO4 (2 weeks into EPO) vs. Base1, C=EPO5 (4 weeks into EPO) vs. 
Base1, D=Post6 (1 week post EPO) vs. Base1, E=Post7 (2 weeks post EPO) vs. Base1, 
F=Post8 (4 weeks post EPO) vs. Base1 (Figure 1B). (B) Differentiation of the red blood cells 
altered by rHuEPO (two time points are presented). (C) Changes in reticulocyte and 
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haematocrit in SCO (n = 18; circle) and KEN (n = 20; square) across the time points. The 
median values of each time point are represented by the coloured lines for SCO (right) and 
KEN (left). 
 
 
Figure 3. Heat map of changes in expression in the fifty genes further validated using 
QuantiGene. Changes are reported as the median log ratio compared to baseline values (n = 
18 and 20 in SCO and KEN, respectively). 
 
Figure 4. Relationship between changes in reticulocyte and genes that remained significantly 
differentially expressed after controlling for the effect of reticulocyte. 
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Table 1. List of genes identified by the microarray experiment  
1A List of the 32 genes (Figure 1C) 
Gene symbol NCBI  Illumina ID Gene name 
ALAS2 NM_000032.1 ILMN_1708323 aminolevulinate, delta-, synthase 2 
BCL2L1 NM_138578.1 ILMN_1654118 BCL2-like 1 
BPGM NM_001724.3 ILMN_2352921 2,3-bisphosphoglycerate mutase 
C1ORF128 NM_020362.2 ILMN_1784207 chromosome 1 open reading frame 128 
CA1 NM_001738.1 ILMN_1652431 carbonic anhydrase I 
E2F2 NM_004091.2 ILMN_1777233 E2F transcription factor 2 
EPB42 NM_000119.1 ILMN_1814397 erythrocyte membrane protein band 4.2 
FAM46C NM_017709.2 ILMN_1713266 family with sequence similarity 46, member C 
FECH NM_000140.2 ILMN_1774091 ferrochelatase 
GMPR NM_006877.2 ILMN_1729487 guanosine monophosphate reductase 
GYPB NM_002100.3 ILMN_1683093 glycophorin B 
GYPE NM_002102.2 ILMN_1695187 glycophorin E 
HBD NM_000519.3 ILMN_1815527 hemoglobin, delta 
IFI27 NM_005532.3 ILMN_2058782 interferon, alpha-inducible protein 27 
KRT1 NM_006121.2 ILMN_1735712 keratin 1 
LOC100131164 XM_001721919.1 ILMN_3285762 PREDICTED: similar to anion exchanger 
LOC441455 XR_041340.1 ILMN_3278170 PREDICTED: misc_RNA 
MARCH8 NM_145021.4 ILMN_2336335 membrane-associated ring finger (C3HC4) 8 
OSBP2 NM_030758.3 ILMN_1781966 oxysterol binding protein 2 
RAP1GAP NM_002885.1 ILMN_1776519 RAP1 GTPase activating protein 
RBM38 NM_183425.1 ILMN_2404049 RNA binding motif protein 38 (transcript variant 2) 
RBM38 NM_017495.4 ILMN_1704079 RNA binding motif protein 38 (transcript variant 1) 
SELENBP1 NM_003944.2 ILMN_1680652 selenium binding protein 1 
SIAH2 NM_005067.5 ILMN_1801313 seven in absentia homolog 2 
SLC4A1 NM_000342.1 ILMN_1772809 solute carrier family 4, anion exchanger, member 1 
SLC6A10P NM_198857.1 ILMN_1704446 solute carrier family 6, member 10 
SNCA NM_007308.1 ILMN_1701933 synuclein, alpha (transcript variant NACP112) 
SNCA NM_000345.2 ILMN_1766165 synuclein, alpha (transcript variant NACP140) 
TMOD1 NM_003275.1 ILMN_1736911 tropomodulin 1 
WDR40A NM_015397.1 ILMN_1786328 WD repeat domain 40A 
XK NM_021083.2 ILMN_1759117 X-linked Kx blood group 
YOD1 NM_018566.3 ILMN_1678919 YOD1 OTU deubiquinating enzyme 1 homolog 
    
1B List of the 5 genes (Figure 1C) 
Gene symbol NCBI  Illumina ID Gene name 
ALAS2 NM_001037968.1 ILMN_2367126 aminolevulinate, delta-, synthase 2 
LOC389599 XM_372002.3 ILMN_1714765 PREDICTED: similar to amyotrophic lateral sclerosis 2 
SELENBP1 NM_003944.2 ILMN_1680652 selenium binding protein 1 
SNCA NM_007308.1 ILMN_1701933 synuclein, alpha 
TRIM58 NM_015431.2 ILMN_1705458 tripartite motif-containing 58 
 
List of the 32 and 5 genes differentially and commonly expressed in both groups during and post rHuEPO 
administration identified by the microarray experiment (Figure 1C).	  
Jérôme Durussel  7/1/2016 21:05
Deleted: 2A
DURUSSEL et al  TRANSCRIPTIONAL SIGNATURE OF rHuEPO 
27 | 
Table 2. Subset of identified genes further analysed using QuantiGene 
GENE.QG NCBI Genbank: Pattern 
Corr QG vs. 
Illumina 
Limma Sig Corr QG vs. 
Ret 
Limma Ret Sig 
A B C D E F A B C D E F 
EPB42 NM_000119 UpDown 0.98(0.98 to 0.98) A-21 B-64 C-44 D-10 E-42 F-14 0.91(0.89 to 0.93) A-3 B-3 C-2 D-3 
  GMPR NM_006877 UpDown 0.98(0.97 to 0.98) A-15 B-49 C-33 D-11 E-53 F-17 0.91(0.88 to 0.93) 
   
D-3 E-3 
 SELENBP1 NM_003944 UpDown 0.98(0.98 to 0.99) A-21 B-64 C-43 D-12 E-50 F-16 0.91(0.89 to 0.93) A-3 B-2 
 
D-4 E-2 
 CA1 NM_001738 UpDown 0.96(0.95 to 0.97) A-14 B-68 C-53   E-46 F-22 0.91(0.88 to 0.92) 
 
B-3 C-4   E-2 
 SLC4A1 NM_000342 UpDown 0.97(0.97 to 0.98) A-19 B-60 C-41 D-8 E-59 F-19 0.92(0.90 to 0.94) A-2 
  
D-2 E-3 
 TRIM58 NM_015431 UpDown 0.97(0.97 to 0.98) A-16 B-55 C-41 D-3 E-51 F-13 0.91(0.88 to 0.93) 
   
  E-2  
BCL2L1 NM_001191 UpDown 0.96(0.95 to 0.97) A-14 B-46 C-36 D-5 E-48 F-16 0.91(0.88 to 0.93) 
   
  E-2 
 CSDA NM_003651 UpDown 0.95(0.93 to 0.96) A-7 B-53 C-40   E-55 F-22 0.91(0.89 to 0.93)  
  
  E-3 
 TMOD1 NM_003275 UpDown 0.94(0.93 to 0.95) A-7 B-39 C-28 D-3 E-51 F-18 0.91(0.89 to 0.93)   
  
  E-3 
 BPGM NM_001724 UpDown 0.87(0.84 to 0.89) A-14 B-48 C-36   E-48 F-20 0.90(0.87 to 0.92)   
  
  E-3 
 DCAF12 NM_015397 UpDown 0.95(0.94 to 0.96) A-8 B-40 C-30   E-55 F-16 0.91(0.89 to 0.93)    
 
  E-3 
 FAM46C NM_017709 UpDown 0.84(0.80 to 0.87) A-7 B-32 C-25   E-51 F-18 0.89(0.86 to 0.91)     
 
  E-3 
 STRADB NM_018571 UpDown 0.96(0.96 to 0.97) A-5 B-34 C-26   E-52 F-19 0.90(0.87 to 0.92)     
 
  E-2 
 ADIPOR1 NM_015999 UpDown 0.97(0.96 to 0.97) A-6 B-39 C-29   E-53 F-20 0.90(0.88 to 0.92)   
  
  E-3 
 HBD NM_000519 UpDown 0.93(0.91 to 0.94) A-5 B-23 C-18 D-2 E-54 F-16 0.88(0.85 to 0.91)       E-3 
 ALAS2 NM_000032 UpDown 0.93(0.92 to 0.95) A-11 B-41 C-31 D-3 E-69 F-23 0.90(0.88 to 0.92)     
 
  E-4 
 PITHD1 NM_020362 UpDown 0.93(0.92 to 0.95) A-19 B-63 C-48   E-30 F-8 0.88(0.86 to 0.91) A-3 B-6 C-6   
  RBM38 NM_017495 UpDown 0.96(0.95 to 0.97) A-15 B-56 C-40   E-38 F-10 0.92(0.90 to 0.93) 
 
B-2 
 
  
 
 
GYPE NM_002102 UpDown 0.89(0.87 to 0.91) A-8 B-39 C-36 D-2 E-11 F-10 0.85(0.82 to 0.88)  B-4 C-6 D-2  
 SNCA NM_000345 UpDown 0.92(0.90 to 0.94) A-7 B-48 C-40 D-2 E-49 F-18 0.89(0.86 to 0.91)   
  
D-3 E-2 
 YOD1 NM_018566 UpDown 0.77(0.72 to 0.81) A-5 B-27 C-25 D-3 E-40 F-16 0.85(0.82 to 0.88)    
 
D-3 E-2 
 FECH NM_000140 UpDown 0.88(0.85 to 0.90) A-8 B-41 C-35   E-37 F-16 0.89(0.87 to 0.92)   
     FBXO7 NM_001033024 UpDown 0.93(0.91 to 0.94) A-4 B-18 C-15   E-38 F-13 0.84(0.80 to 0.87)      E-2 
 UBXN6 NM_025241 UpDown 0.97(0.96 to 0.97) A-5 B-35 C-25   E-53 F-20 0.91(0.88 to 0.93)         E-3 
 GUK1 NM_000858 UpDown 0.97(0.96 to 0.98) A-4 B-22 C-15 D-3 E-55 F-23 0.91(0.89 to 0.93)         E-3 
 KRT1 NM_006121 UpDown 0.77(0.71 to 0.81) A-3 B-14 C-10       0.74(0.69 to 0.79)   B-4 C-4     
 ROPN1B NM_001012337 UpDown 0.81(0.76 to 0.84) A-3 B-13 C-10   E-6 F-2 0.77(0.72 to 0.82)   B-3 C-2      
SERPINA13 NM_207378 UpDown 0.76(0.70 to 0.80) A-2 B-9 C-13   E-5   0.74(0.68 to 0.79)   B-2 C-4     
 OSBP2 NM_030758 UpDown 0.51(0.42 to 0.59)   B-9 C-10 D-3 E-4 F-11 0.52(0.43 to 0.60)   B-4 C-5   E-2 F-4 
HBE1 NM_005330 UpDown 0.56(0.48 to 0.64)   B-4 C-4     F-4 0.54(0.45 to 0.61)   B-2 C-3     
 SLC6A10P NM_198857 UpDown 0.35(0.24 to 0.44)     C-2 D-3 E-7 F-13 0.31(0.20 to 0.41)   
 
C-3   E-2 F-3 
VEGFB NM_003377 DownUp -0.26(-0.36 to -0.15)     C-2 D-3 E-8 F-11 0.40(0.30 to 0.49)   
 
C-2   E-3 F-3 
TPRA1 NM_016372 UpDown 0.47(0.37 to 0.55)           F-2 0.44(0.34 to 0.53)   B-2 C-3       
TNS1 NM_022648 UpDown 0.86(0.83 to 0.89) A-6 B-7 C-4 D-2 E-12 F-3 0.78(0.73 to 0.82)           
 SGK223 NM_001080826 DownUp 0.21(0.09 to 0.31)   B-13 C-4   E-5 F-11 0.04(-0.07 to 0.16)           
 ACTR10 NM_018477 HK 0.06(-0.06 to 0.17)   B-8 C-4   E-4 F-2 0.29(0.18 to 0.39)           
 MRFAP1 NM_033296 HK 0.15(0.04 to 0.26)   B-20 C-16   E-2 F-2 0.07(-0.05 to 0.19)         E-2  
RAB11A NM_004663 HK 0.21(0.10 to 0.32)   B-12 C-9   E-2   0.09(-0.03 to 0.20)         E-2 
 ACTB NM_001101 HK 0.30(0.19 to 0.41)   B-16 C-13   E-7 F-3 -0.38(-0.48 to -0.28)            
CD3D NM_000732 DownUp 0.93(0.91 to 0.94) A-3 B-51 C-32   E-6 F-3 -0.63(-0.69 to -0.55)   
  
  E-2  
 CCR7 NM_001838 DownUp 0.94(0.92 to 0.95)   B-48 C-31   E-9 F-7 -0.60(-0.67 to -0.52)   
  
     
LEF1 NM_016269 DownUp 0.93(0.91 to 0.94) A-2 B-46 C-29   E-8 F-5 -0.62(-0.69 to -0.55)   
 
   E-2 
 SKAP1 NM_003726 DownUp 0.87(0.83 to 0.89)   B-34 C-20   E-4 F-3 -0.45(-0.54 to -0.36)   
 
       
RNF213 NM_020914 UpDown -0.47(-0.56 to -0.38) A-3 B-29 C-18   E-3 F-2 -0.40(-0.50 to -0.30)          
 PPIB NM_000942 HK 0.38(0.27 to 0.47) A-2 B-43 C-27   E-4 F-2 -0.54(-0.62 to -0.45)   
 
    E-2  
MIF NM_002415 DownUp 0.84(0.80 to 0.87) A-3 B-47 C-31   E-5   -0.60(-0.67 to -0.52)   
  
  E-2  
 EEF1D NM_032378 DownUp 0.66(0.58 to 0.72) A-2 B-48 C-33   E-8 F-4 -0.63(-0.69 to -0.55)   
 
   E-2   
LOC286444 XR_038693 DownUp 0.63(0.55 to 0.69) A-4 B-55 C-32   E-9 F-5 -0.65(-0.71 to -0.58)   
  
  E-2  
 CD247 NM_198053 DownUp 0.92(0.90 to 0.94) A-3 B-42 C-26   E-3   -0.52(-0.60 to -0.43)   
  
  E-3  
LOC100130562 XM_001720379 DownUp 0.59(0.51 to 0.66) A-2 B-44 C-29   E-6 F-3 -0.59(-0.66 to -0.51)       E-2 
 The subset of identified genes further validated using QuantiGene (QG) Plex assay is arranged according to the heatmap (Figure 3A). The columns 
are: (1) Gene name; (2) Accession number; (3) Physiological identified pattern (UpDown: Up-regulated during rHuEPO and down-regulated post 
administration; DownUp: Down-regulated during rHuEPO and up-regulated post administration; HK: Housekeeping genes); (4 and 6) Correlation 
between QG and Illumina and QG and reticulocyte results, respectively (r(95% CI)); (5 and 7) Significant difference in expression (exponent of the FDR adjusted 
p-value) at the time points described in Figure 1B using linear models for microarray (Limma) before and after removing the effect of reticulocyte, 
respectively. Labels for comparisons: A=EPO3 (2 days into EPO dosing) vs. Base1 (first baseline measurement), B=EPO4 (2 weeks into EPO) vs. 
Base1, C=EPO5 (4 weeks into EPO) vs. Base1, D=Post6 (1 week post EPO) vs. Base1, E=Post7 (2 weeks post EPO) vs. Base1, F=Post8 (4 weeks 
post EPO) vs. Base1. 
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Table 3. Results of the k-nearest neighbour class prediction using the 34 transcripts for 
the detection of rHuEPO 
 
3A Baseline rHuEPO Post 
Baseline 23.8% 5.4% 10.0% 
rHuEPO 0.7% 31.0% 1.5% 
Post 0.7% 1.0% 25.8% 
 
 
3B Base1 Base2 EPO3 EPO4 EPO5 Post6 Post7 Post8 
Baseline 11.9% 11.9% 4.7% 0.0% 0.7% 4.6% 1.5% 3.9% 
rHuEPO 0.7% 0.0% 7.2% 12.3% 11.6% 1.0% 0.2% 0.3% 
Post 0.0% 0.7% 0.3% 0.3% 7.0% 7.0% 10.5% 8.4% 
 
The top row represents the observed phases (3A) or time points (3B) and the first column 
represents the k-nearest neighbour predictions. The results highlighted with a grey 
background are correctly classified results in percentage. The majority of the 
misclassifications affecting the sensitivity of the detection of rHuEPO arose at two days after 
only rHuEPO injection (EPO3) and one week after ceasing rHuEPO administration (Post6), 
when the gene expression is crossing baseline levels due to the “rebound” effect. 34 
Transcripts: EPB42, GMPR, SELENBP1, CA1, SLC4A1, TRIM58, BCL2L1, CSDA, TMOD1, 
BPGM, DCAF12, FAM46C, STRADB, ADIPOR1, HBD, ALAS2, PITHD1, RBM38, GYPE, 
SNCA, YOD1, FECH, FBXO7, UBXN6, GUK1, CD3D, CCR7, LEF1, SKAP1, MIF, EEF1D, 
LOC286444, CD247, LOC100130562. 
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